Regentis Biomaterials Ltd. (RGNT) - Total Assets
Based on the latest financial reports, Regentis Biomaterials Ltd. (RGNT) holds total assets worth $7.62 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Regentis Biomaterials Ltd. stock price for real-time trading data and today's change.
Regentis Biomaterials Ltd. - Total Assets Trend (2022–2025)
This chart illustrates how Regentis Biomaterials Ltd.'s total assets have evolved over time, based on quarterly financial data. Also see RGNT operating cash flow for how efficiently the company converts equity into cash flow.
Regentis Biomaterials Ltd. - Asset Composition Analysis
Current Asset Composition (December 2025)
Regentis Biomaterials Ltd.'s total assets of $7.62 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 96.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how Regentis Biomaterials Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of Regentis Biomaterials Ltd. to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Regentis Biomaterials Ltd.'s current assets represent 100.0% of total assets in 2025, unchanged from 100.0% in 2022.
- Cash Position: Cash and equivalents constituted 96.9% of total assets in 2025, up from 72.2% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Regentis Biomaterials Ltd. Competitors by Total Assets
Key competitors of Regentis Biomaterials Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tinavi Medical Technologies Co Ltd
SHG:688277
|
China | CN¥1.64 Billion |
|
Medeon Biodesign
TWO:6499
|
Taiwan | NT$1.68 Billion |
|
Interojo Inc
KQ:119610
|
Korea | ₩252.22 Billion |
|
I.Ceram SA
PA:ALICR
|
France | €3.91 Million |
|
Ansell Ltd
AU:ANN
|
Australia | AU$3.33 Billion |
|
Nanosonics Ltd
AU:NAN
|
Australia | AU$279.25 Million |
|
SDI Ltd
AU:SDI
|
Australia | AU$135.84 Million |
|
Austco Healthcare Ltd
AU:AHC
|
Australia | AU$91.07 Million |
Regentis Biomaterials Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.65 | 0.07 | 0.07 |
| Quick Ratio | 2.65 | 0.07 | 0.07 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $4.74 Million | $-6.01 Million | $-6.01 Million |
Regentis Biomaterials Ltd. - Advanced Valuation Insights
This section examines the relationship between Regentis Biomaterials Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.80 |
| Latest Market Cap to Assets Ratio | 1.74 |
| Asset Growth Rate (YoY) | 1480.5% |
| Total Assets | $7.62 Million |
| Market Capitalization | $13.28 Million USD |
Valuation Analysis
Above Book Valuation: The market values Regentis Biomaterials Ltd.'s assets above their book value (1.74x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Regentis Biomaterials Ltd.'s assets grew by 1480.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Regentis Biomaterials Ltd. (2022–2025)
The table below shows the annual total assets of Regentis Biomaterials Ltd. from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $7.62 Million | +1480.50% |
| 2024-12-31 | $482.00K | +33.89% |
| 2023-12-31 | $360.00K | -79.03% |
| 2022-12-31 | $1.72 Million | -- |
About Regentis Biomaterials Ltd.
Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical tr… Read more